Aged
Carboxylic Acids
/ administration & dosage
Contrast Media
/ administration & dosage
Cyclobutanes
/ administration & dosage
Edetic Acid
/ administration & dosage
Gallium Isotopes
Gallium Radioisotopes
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ blood
Oligopeptides
/ administration & dosage
Positron Emission Tomography Computed Tomography
/ methods
Prospective Studies
Prostate-Specific Antigen
/ blood
Prostatectomy
/ methods
Prostatic Neoplasms
/ blood
Journal
The Lancet. Oncology
ISSN: 1474-5488
Titre abrégé: Lancet Oncol
Pays: England
ID NLM: 100957246
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
26
03
2019
revised:
01
06
2019
accepted:
03
06
2019
pubmed:
4
8
2019
medline:
1
7
2020
entrez:
4
8
2019
Statut:
ppublish
Résumé
National Comprehensive Cancer Network guidelines consider This was a prospective, single-centre, open-label, single-arm comparative study done at University of California Los Angeles (Los Angeles, CA, USA). Patients older than 18 years of age with prostate cancer biochemical recurrence after radical prostatectomy and PSA levels ranging from 0·2 to 2·0 ng/mL without any prior salvage therapy and with a Karnofsky performance status of at least 50 were eligible. Patients underwent Between Feb 26, 2018, and Sept 20, 2018, 143 patients were screened for eligibility, of whom 50 patients were enrolled into the study. Median follow-up was 8 months (IQR 7-9). The primary endpoint was met; detection rates were significantly lower with With higher detection rates, PSMA should be the PET tracer of choice when PET-CT imaging is considered for subsequent treatment management decisions in patients with prostate cancer and biochemical recurrence after radical prostatectomy and low PSA concentrations (≤2·0 ng/mL). Further research is needed to investigate whether higher detection rates translate into improved oncological outcomes. None.
Sections du résumé
BACKGROUND
National Comprehensive Cancer Network guidelines consider
METHODS
This was a prospective, single-centre, open-label, single-arm comparative study done at University of California Los Angeles (Los Angeles, CA, USA). Patients older than 18 years of age with prostate cancer biochemical recurrence after radical prostatectomy and PSA levels ranging from 0·2 to 2·0 ng/mL without any prior salvage therapy and with a Karnofsky performance status of at least 50 were eligible. Patients underwent
FINDINGS
Between Feb 26, 2018, and Sept 20, 2018, 143 patients were screened for eligibility, of whom 50 patients were enrolled into the study. Median follow-up was 8 months (IQR 7-9). The primary endpoint was met; detection rates were significantly lower with
INTERPRETATION
With higher detection rates, PSMA should be the PET tracer of choice when PET-CT imaging is considered for subsequent treatment management decisions in patients with prostate cancer and biochemical recurrence after radical prostatectomy and low PSA concentrations (≤2·0 ng/mL). Further research is needed to investigate whether higher detection rates translate into improved oncological outcomes.
FUNDING
None.
Identifiants
pubmed: 31375469
pii: S1470-2045(19)30415-2
doi: 10.1016/S1470-2045(19)30415-2
pmc: PMC7469487
mid: NIHMS1623083
pii:
doi:
Substances chimiques
Carboxylic Acids
0
Contrast Media
0
Cyclobutanes
0
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
gallium 68 PSMA-11
0
fluciclovine F-18
38R1Q0L1ZE
Edetic Acid
9G34HU7RV0
Prostate-Specific Antigen
EC 3.4.21.77
Banques de données
ClinicalTrials.gov
['NCT02940262']
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1286-1294Subventions
Organisme : NCI NIH HHS
ID : R01 CA212148
Pays : United States
Organisme : NIBIB NIH HHS
ID : R21 EB017568
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : ErratumIn
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
J Nucl Med. 2018 Sep;59(9):1406-1411
pubmed: 29371407
J Urol. 2019 Feb;201(2):322-331
pubmed: 30179618
J Nucl Med. 2018 May;59(5):789-794
pubmed: 29242404
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Clin Nucl Med. 2018 Dec;43(12):909-917
pubmed: 30325827
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1256-64
pubmed: 23613104
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83
pubmed: 27091135
JAMA Oncol. 2019 Jun 1;5(6):856-863
pubmed: 30920593
J Nucl Med. 2017 Oct;58(10):1617-1623
pubmed: 28408531
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
J Urol. 2017 Mar;197(3 Pt 1):676-683
pubmed: 27746282
Radiographics. 2018 Jan-Feb;38(1):200-217
pubmed: 29320333
Cancer Res. 2011 Dec 15;71(24):7525-36
pubmed: 22007000
Am Soc Clin Oncol Educ Book. 2016;35:119-29
pubmed: 27249693
J Nucl Med. 2015 Aug;56(8):1185-90
pubmed: 26112024
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209
pubmed: 25411132
J Nucl Med. 2019 Jun;60(6):786-793
pubmed: 30530831
J Nucl Med. 2004 May;45(5):797-801
pubmed: 15136629
J Nucl Med. 2017 Oct;58(10):1596-1602
pubmed: 28385791
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1601-10
pubmed: 26960562
Pathol Oncol Res. 2009 Jun;15(2):167-72
pubmed: 18802790
Nutrients. 2017 Dec 26;10(1):
pubmed: 29278358
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541